The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto
The newly launched tools aim to reduce the time and costs of marketing new drugs by "debugging" the lab environment.
Finicky formulary committees and rising consumer cost consciousness add up to a new market dynamic for health brands. A new survey helps break it down.
It's the industry's biggest turnout in the Super Bowl in three years.
PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team
Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog
The Ketchum veteran joined the nonprofit healthcare system in mid-2014.
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Burcin's charge is to keep momentum going at the indie agency, known for placing ice-cream carts outside of rival agencies and other recruiting tactics.
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet